Corresponding cumulative incidences for CRC were 50.3% (95% CI (43.8–56.8)) versus 61.6% (95% CI (45.9–77.4)) for path_MLH1 carriers and 47.3% (95% CI (39.6–55.1)) versus 49.9% (95% CI (36.4–63.4)) for path_MSH2 carriers with truncating or missense/aberrant splicing variants, respectively. Here, MSH2 is linked to colorectal carcinoma.